Cancer treatment response study for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study uses special scans to see how well the drug Pluvicto is working in men with metastatic prostate cancer. You would have two PET scans, one before starting treatment and one after 12 weeks, to check your cancer's response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with metastatic prostate cancer.
- You are scheduled to start treatment with a drug called Pluvicto (177Lu-PSMA).
- You are able to have two PET/CT scans using 68Ga-PSMA or 18F-DCFPyL, one before starting and one after 12 weeks of treatment.
- Your daily activity level is good enough that you can care for yourself and be up and about at least half of the day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This trial studies how well a radioactive drug called Pluvicto works in men with prostate cancer who also have kidney or bone marrow problems. You'll get the treatment and have several scans to see how the drug affects your body.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.